Pharmaceutical New Development 2011 Overview - Key strategic trends Market Overview in the pharmaceutical Market Overview in dustry

• Publication date: May 2011

About This Report A number of factors have and will continue to impact pharmaceutical sales and profits going forward. As a result of rising healthcare costs, healthcare budgets are being stretched. Healthcare payers are also feeling the impact of the global economic downturn. As a result, payers are introducing a number of cost-containment strategies as well as tougher regulatory measures What's Included in This Re...

About This Report

A number of factors have and will continue to impact pharmaceutical sales and profits going forward. As a result of rising healthcare costs, healthcare budgets are being stretched.
Healthcare payers are also feeling the impact of the global economic downturn.
As a result, payers are introducing a number of cost-containment strategies as well as tougher regulatory measures

What's Included in This Report?


* An overview of drivers of rising healthcare costs

* Review the impact of the global economic downturn on the healthcare and the pharmaceutical market

* Assess the growing cost-containment and regulatory pressures facing pharma

* An overview of the impact of the patent expiries on pharma together with the market ’s responses

Key Market Facts

Aging populations, the growing prevalence of chronic disease, greater use of expensive treatments, and grow ing public healthcare coverage are stretching existing healthcare resources. As a result of rising unemployment, healthcare payers are also feeling the impact of the global economic downturn through reduced funding via taxation.
In response, payers are introducing a number of cost-containment strategies, such as reducing healthcare budgets and implementing pricing and reimbursement cuts, as well as bolstering generic uptake. These measures, together with the increasingly tough regulatory environment, all have a negative impact on the pharmaceutical market .
Branded pharmaceutical industry players are set to lose approximately USD 100bn in sales due to the patent cliff and the resultant generic erosion of branded sales during 2010–15 in the seven major industries, while the market is also feeling the effects of the recent global economic downturn both directly and indirectly.

Why Should You Buy This Report?


* Evaluate factors driving healthcare costs in the developed and emerging industries, and how the economic downturn has impacted the healthcare landscape

* Get detailed data into the impact that the patent cliff as well as growing use of biosimilars will have on branded pharma sales out to 2015

* Review the growing cost-containment and regulatory measures facing pharma, as well as the market ’s response to grow profitability going forward

Pharmaceutical Industry

Summary
Strategic scoping and focus
Main Facts
DRIVERS OF RISING HEALTHCARE COSTS
Demographic trends in the major developed and emerging industry s
Aging patient populations
Growing prevalence of chronic diseases
Greater use of expensive treatments – pharmaceutical spending is increasing in all industry s
Expanding pubic healthcare coverage
IMPACT OF THE GLOBAL ECONOMIC DOWNTURN ON HEALTHCARE AND PHARMA
Impact of the economic downturn on both developed and emerging industry s
Growing uninsured population – US patients are less able to cover the costs of healthcare, including pharmaceuticals
Government strategies to cut the budget deficit target healthcare and pharmaceutical spending
COST-CONTAINMENT AND REGULATORY PRESSURES
Government strategies to contain healthcare and pharma costs
Healthcare spending has slowed in several industry s as governments bring in austerity measures
Pricing and reimbursement cuts were key elements included in austerity measures in many developed industry s
Regulatory changes have a largely negative impact on pharma
Healthcare systems globally are converging toward a similar model
Driving generic uptake will create further savings
THE PATENT CLIFF
The patent cliff represents a major resistor to branded pharma growth
Branded pharma set to lose USD 82bn due to the patent cliff
Biosimilar uptake is set to accelerate
PHARMA’S STRATEGIC RESPONSES TO DRIVE PROFITABILITY
Pharma innovates, diversifies, and contains cost in order to grow profits
Pharma’s strategic responses to drive sales and profitability
Innovation – pharma sharpens its focus on secondary care indications through high value biologic therapies
Diversification – growth in global industry s will more than offset sales decline in the US
Cost-cutting – pharma cuts cost to increase margins
The impact of pharma’s strategic responses on projection sales during 2010–15
BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
Exchange rates used in this report